Skip to main content

Articles

Page 6 of 16

  1. Germ-line mutations in several genes, such as BRCA1 and BRCA2, are known to increase the risk of breast cancer. These heritable mutations are unequally represented among populations with different ethnic backgrou...

    Authors: Ielizaveta Gorodetska, Svitlana Serga, Natalia Levkovich, Tetiana Lahuta, Ludmila Ostapchenko, Serhyi Demydov, Nikolay Anikusko, Valeriy Cheshuk, Ivan Smolanka, Svitlana Sklyar, Serhyi Polenkov, Oleksander Boichenko and Iryna Kozeretska
    Citation: Hereditary Cancer in Clinical Practice 2015 13:19
  2. Authors: Szymon Hryhorowicz, Katarzyna Ziemnicka, Marta Kaczmarek-Rys, Justyna Hoppe-Golebiewska, Andrzej Plawski, Marzena Skrzypczak-Zielinska, Monika Golab, Malgorzata Szkudlarek, Batlomiej Budny, Marek Ruchala and Ryszard Slomsk
    Citation: Hereditary Cancer in Clinical Practice 2015 13(Suppl 1):A15

    This article is part of a Supplement: Volume 13 Supplement 1

  3. Authors: Marcin Lener, Anna Wiechowska-Kozlowska, Rodney J Scott, Magdalena Muszynska, Jozef Kladny, Piotr Waloszczyk, Anna Rutkowska, Grzegorz Sukiennicki, Tomasz Gromowski, Katarzyna Jaworska-Bieniek, Thierry van de Wetering, Katarzyna Kaczmarek, Anna Jakubowska and Jan Lubinski
    Citation: Hereditary Cancer in Clinical Practice 2015 13(Suppl 1):A14

    This article is part of a Supplement: Volume 13 Supplement 1

  4. Genetic screening in families with high risk to develop colorectal cancer (CRC) prevents incurable disease and permits personalized therapeutic and follow-up strategies. The advancement of next-generation sequ...

    Authors: Michele Simbolo, Andrea Mafficini, Marco Agostini, Corrado Pedrazzani, Chiara Bedin, Emanuele D. Urso, Donato Nitti, Giona Turri, Maria Scardoni, Matteo Fassan and Aldo Scarpa
    Citation: Hereditary Cancer in Clinical Practice 2015 13:18
  5. Screening for BRCA 1 and BRCA 2 mutations has long moved from the research lab to the clinic as a routine clinical genetic testing. BRCA molecular alteration pattern varies among ethnic groups which makes it a...

    Authors: Alexandra Tsigginou, Fotios Vlachopoulos, Iordanis Arzimanoglou, Flora Zagouri and Constantine Dimitrakakis
    Citation: Hereditary Cancer in Clinical Practice 2015 13:17
  6. Approximately 30 % of all breast cancer is at least partly attributed to hereditary factors. Familial breast cancer is often inherited in the context of cancer syndromes. The most commonly mutated genes are BR...

    Authors: Camilla Wendt, Annika Lindblom, Brita Arver, Anna von Wachenfeldt and Sara Margolin
    Citation: Hereditary Cancer in Clinical Practice 2015 13:15
  7. Common genetic variants have been shown to modify BRCA1 penetrance. The aim of this study was to validate these reports in a special cohort of Norwegian BRCA1 mutation carriers that were selected for their extrem...

    Authors: Cecilie Heramb, Per Olaf Ekstrøm, Kukatharmini Tharmaratnam, Eivind Hovig, Pål Møller and Lovise Mæhle
    Citation: Hereditary Cancer in Clinical Practice 2015 13:14
  8. Pancreatic cancer (PancCa) is recognized as a component of many well-described hereditary cancer syndromes. Minimal research has focused on patient needs and experiences living with this risk.

    Authors: Meghan Underhill, Donna Berry, Emily Dalton, Jaclyn Schienda and Sapna Syngal
    Citation: Hereditary Cancer in Clinical Practice 2015 13:13
  9. Advancements in genomic testing have led to the identification of single nucleotide polymorphisms (SNPs) associated with prostate cancer. The clinical utility of SNP tests to evaluate prostate cancer risk is u...

    Authors: Michael J Hall, Karen J Ruth, David YT Chen, Laura M Gross and Veda N Giri
    Citation: Hereditary Cancer in Clinical Practice 2015 13:11
  10. Women who carry a mutation for Lynch syndrome face complex decisions regarding strategies for managing their increased cancer risks. At present, there is limited understanding of the factors influencing women’...

    Authors: Holly Etchegary, Elizabeth Dicks, Kathy Watkins, Sabrina Alani and Lesa Dawson
    Citation: Hereditary Cancer in Clinical Practice 2015 13:10
  11. The editors of Hereditary Cancer in Clinical Practice would like to thank all our reviewers who have contributed to the journal in 2014.

    Authors: Jan Lubinski, Rodney J Scott, Rolf Sijmons and Katie Bayliss
    Citation: Hereditary Cancer in Clinical Practice 2015 13:9
  12. Differentiated thyroid carcinoma (DTC) originates from thyroid follicular epithelial cells and belongs to a group of slowly progressing tumors with a relatively good prognosis. However, recurrences and metasta...

    Authors: Marta Kaczmarek-Ryś, Katarzyna Ziemnicka, Szymon T Hryhorowicz, Katarzyna Górczak, Justyna Hoppe-Gołębiewska, Marzena Skrzypczak-Zielińska, Michalina Tomys, Monika Gołąb, Malgorzata Szkudlarek, Bartłomiej Budny, Idzi Siatkowski, Paweł Gut, Marek Ruchała, Ryszard Słomski and Andrzej Pławski
    Citation: Hereditary Cancer in Clinical Practice 2015 13:8
  13. Hereditary triple-negative breast cancer patients have better recurrence-free survival than triple-negative sporadic ones. High expression of some of the miRNAs is related to worse overall and disease-free sur...

    Authors: Dagnija Kalniete, Miki Nakazawa-Miklaševiča, Ilze Štrumfa, Arnis Āboliņš, Arvīds Irmejs, Jānis Gardovskis and Edvīns Miklaševičs
    Citation: Hereditary Cancer in Clinical Practice 2015 13:7
  14. A 46-year-old female presents with a pelvic mass and is diagnosed as having a high-grade endometrial stromal sarcoma. During surgery, she is noted to have areas of intussusception of the small bowel secondary ...

    Authors: Maria Fernanda Noriega-Iriondo, Gerardo Colon-Otero, Benjamin R Kipp, John A Copland, Matthew J Ferber, Laura A Marlow, Maegan E Roberts, Matthew W Robertson, Tri A Dinh, Steven Attia, Xochiquetzal J Geiger and Douglas L Riegert-Johnson
    Citation: Hereditary Cancer in Clinical Practice 2015 13:6
  15. Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant inherited endocrine malignancy syndrome. Early and normative surgery is the only curative method for MEN 2-related medullary thyroid carcinom...

    Authors: Jian-Qiang Zhao, Zhen-Guang Chen and Xiao-Ping Qi
    Citation: Hereditary Cancer in Clinical Practice 2015 13:5
  16. Poly (ADP-ribose) polymerases, abbreviated as PARPs, are a group of familiar proteins that play a central role in DNA repair employing the base excision repair (BER) pathway. There about 17 proteins in this fa...

    Authors: Maheen Anwar, Hafiz Muhammad Aslam and Shahzad Anwar
    Citation: Hereditary Cancer in Clinical Practice 2015 13:4
  17. Over half the cancer deaths in HNPCC families are due to extra-colonic malignancies that include endometrial and ovarian cancers. The benefits of surveillance for gynecological cancers are not yet proven and t...

    Authors: Tadeusz Dębniak, Tomasz Gromowski, Rodney J Scott, Jacek Gronwald, Tomasz Huzarski, Tomasz Byrski, Grzegorz Kurzawski, Dagmara Dymerska, Bohdan Górski, Katarzyna Paszkowska-Szczur, Cezary Cybulski, Pablo Serrano-Fernandez and Jan Lubiński
    Citation: Hereditary Cancer in Clinical Practice 2015 13:3
  18. Male breast cancer (MBC) is an uncommon disease that has been the focus of limited research. It is estimated that approximately 10% of men with breast cancer have a genetic predisposition, with BRCA2 being the mo...

    Authors: Ana Rafaela de Souza Timoteo, Betina Menezes Albuquerque, Patricia Pascoto Pascoto Moura, Carlos Cesar de Oliveira Ramos, Lucymara Fassarela Agnez-Lima, Tom Walsh, Mary-Claire King and Tirzah Braz Petta Lajus
    Citation: Hereditary Cancer in Clinical Practice 2015 13:2
  19. Breast cancer is the most common cancer in the UK. Lifestyle factors including excess weight contribute to risk of developing the disease. Whilst the exact links between weight and breast cancer are still emer...

    Authors: Claire E Wright, Michelle Harvie, Anthony Howell, D Gareth Evans, Nick Hulbert-Williams and Louise S Donnelly
    Citation: Hereditary Cancer in Clinical Practice 2015 13:1
  20. MUTYH- associated polyposis (MAP) is an autosomal recessive disease, which predisposes to polyposis and colorectal cancer. There is a trend towards an increased risk of breast cancer in MAP patients, with a rema...

    Authors: Ewout P Boesaard, Ingrid P Vogelaar, Peter Bult, Carla AP Wauters, J Han JM van Krieken, Marjolijn JL Ligtenberg, Rachel S van der Post and Nicoline Hoogerbrugge
    Citation: Hereditary Cancer in Clinical Practice 2014 12:21
  21. Mutations in the CDKN2A and CDK4 genes predispose to melanoma. From three case-control studies of cutaneous melanoma, we estimated the prevalence and predictors of these mutations for people from regions with wid...

    Authors: Mark Harland, Anne E Cust, Celia Badenas, Yu-Mei Chang, Elizabeth A Holland, Paula Aguilera, Joanne F Aitken, Bruce K Armstrong, Jennifer H Barrett, Cristina Carrera, May Chan, Joanne Gascoyne, Graham G Giles, Chantelle Agha-Hamilton, John L Hopper, Mark A Jenkins…
    Citation: Hereditary Cancer in Clinical Practice 2014 12:20
  22. PALB2 has emerged as a breast cancer susceptibility gene. Mutations in PALB2 have been identified in almost all breast cancer populations studied to date, but the rarity of these mutations and lack of informatio...

    Authors: Taila Hartley, Luca Cavallone, Nelly Sabbaghian, Rachel Silva-Smith, Nancy Hamel, Olga Aleynikova, Erika Smith, Valerie Hastings, Pedro Pinto, Marc Tischkowitz, Eva Tomiak and William D Foulkes
    Citation: Hereditary Cancer in Clinical Practice 2014 12:19
  23. Hereditary diffuse gastric cancer (HDGC) is a hereditary autosomal inherited syndrome associated with CDH1 germline mutations. In Brazil, gastrointestinal tumors are among the most prevalent tumor types and const...

    Authors: Caroline Aquino Moreira-Nunes, Mariceli Baia Leão Barros, Bárbara do Nascimento Borges, Raquel Carvalho Montenegro, Leticia Martins Lamarão, Helem Ferreira Ribeiro, Amanda Braga Bona, Paulo Pimentel Assumpção, Juan Antonio Rey, Giovanny Rebouças Pinto and Rommel Rodriguez Burbano
    Citation: Hereditary Cancer in Clinical Practice 2014 12:18
  24. Loss of cadherin 1 (CDH1) expression, which is normally involved in cell adhesion and maintenance of tissue architecture, is a hallmark of invasive lobular carcinoma (ILCA). Because hereditary cancers may requ...

    Authors: Allyson L Valente, Seth Rummel, Craig D Shriver and Rachel E Ellsworth
    Citation: Hereditary Cancer in Clinical Practice 2014 12:17
  25. Patients with intragenic mutations of the VHL gene have a typical disease presentation. However in cases of large VHL gene deletions which involve other genes in the proximity of the VHL gene a presentation of th...

    Authors: Karol Krzystolik, Anna Jakubowska, Jacek Gronwald, Maciej R Krawczyński, Monika Drobek-Słowik, Leszek Sagan, Leszek Cyryłowski, Wojciech Lubiński, Jan Lubiński and Cezary Cybulski
    Citation: Hereditary Cancer in Clinical Practice 2014 12:16
  26. Familial breast cancer (fBC) is generally associated with an early age of diagnosis and a higher frequency of disease among family members. Over the past two decades a number of genes have been identified that...

    Authors: Amy L Masson, Bente A Talseth-Palmer, Tiffany-Jane Evans, Desma M Grice, Garry N Hannan and Rodney J Scott
    Citation: Hereditary Cancer in Clinical Practice 2014 12:15
  27. Uterine cancer (UC) represents 5.1% of all female malignancies in Sweden. Accumulation of UC in families occurs in around 5% of cases. We wanted to identify any familial association between UC and other select...

    Authors: Gerasimos Tzortzatos, Ofra Wersäll, Kristina Gemzell Danielsson, Annika Lindblom, Emma Tham and Miriam Mints
    Citation: Hereditary Cancer in Clinical Practice 2014 12:14
  28. The Wnt proteins are a family of 19 secreted glycoproteins that occupy crucial roles in the regulation of processes such as cell survival, proliferation, migration and polarity, cell fate specification, body a...

    Authors: Asfandyar Sheikh, Asfandyar Khan Niazi, Muhammad Zafar Ahmed, Bushra Iqbal, Syed Muhammad Saad Anwer and Hira Hussain Khan
    Citation: Hereditary Cancer in Clinical Practice 2014 12:13
  29. Using immunohistochemistry (IHC) to select cases for mismatch repair (MMR) genetic testing, we failed to identify a large kindred with the deleterious PMS2 mutation c.989-1G > T. The purpose of the study was to e...

    Authors: Eli Marie Grindedal, Harald Aarset, Inga Bjørnevoll, Elin Røyset, Lovise Mæhle, Astrid Stormorken, Cecilie Heramb, Heidi Medvik, Pål Møller and Wenche Sjursen
    Citation: Hereditary Cancer in Clinical Practice 2014 12:12
  30. Approximately 5% of all breast cancers can be attributed to a mutation in the BRCA1 or BRCA2 gene. The genetic component of breast cancer in Colombia has been, for the most part, studied on cases from the Bogota ...

    Authors: Julián Esteban Londoño Hernández, Marcia Llacuachaqui, Gonzalo Vásquez Palacio, Juan David Figueroa, Jorge Madrid, Mauricio Lema, Robert Royer, Song Li, Garrett Larson, Jeffrey N Weitzel and Steven A Narod
    Citation: Hereditary Cancer in Clinical Practice 2014 12:11
  31. Germline mutations of the CHEK2 gene have been reported to be associated with breast cancer. In this study, we analyzed the association of CHEK2 mutations with the risk of development of breast cancer in women of...

    Authors: Aneta Bąk, Hanna Janiszewska, Anna Junkiert-Czarnecka, Marta Heise, Maria Pilarska-Deltow, Ryszard Laskowski, Magdalena Pasińska and Olga Haus
    Citation: Hereditary Cancer in Clinical Practice 2014 12:10
  32. As BRCA1/2 testing becomes more routine, questions remain about long-term satisfaction and quality of life following testing. Previously, we described long term distress and risk management outcomes among women w...

    Authors: Gillian W Hooker, Lesley King, Lauren VanHusen, Kristi Graves, Beth N Peshkin, Claudine Isaacs, Kathryn L Taylor, Elizabeth Poggi and Marc D Schwartz
    Citation: Hereditary Cancer in Clinical Practice 2014 12:9

Annual Journal Metrics

  • 2022 Citation Impact
    1.7 - 2-year Impact Factor
    2.2 - 5-year Impact Factor
    0.634 - SNIP (Source Normalized Impact per Paper)
    0.526 - SJR (SCImago Journal Rank)

    2023 Speed
    13 days submission to first editorial decision for all manuscripts (Median)
    131 days submission to accept (Median)

    2023 Usage 
    394,813 downloads
    196 Altmetric mentions